Quality of life in people with Parkinson’s disease and its relationship to disease severity
DOI:
https://doi.org/10.47197/retos.v77.112806Keywords:
Parkinson's disease, quality of life, severity, motor symptoms, PDQ-39Abstract
Introduction: The quality of life in people with Parkinson's disease (PD) is influenced by multiple factors, including the severity of the disease. Objectives: To determine the relationship between quality of life and the severity of Parkinson's disease, identifying the most affected factors at each stage of progression.
Methodology: 30 adults with an average age of 51.417±1.80 years from the Parkinson's Association of Valdivia were administered the SF-36 survey to assess health-related quality of life (HRQoL). Additionally, the Hoehn and Yahr scale was used to determine the severity of Parkinson's disease (PD).
Results: According to the SF-36 questionnaire, women showed a better quality of life (55.08%) compared to men (47.75%). The dimensions of physical role (dimension 2) and emotional role (dimension 7) were significantly low, while vitality (dimension 5), mental health (dimension 8), and social functioning (dimension 6) showed significantly higher differences. The Hoehn and Yahr scale revealed that most participants were in a mild to moderate stage of the disease, with stage 3 being the most frequent, 30% in women and 23.33% in men. The predominant signs and symptoms were bradykinesia, resting tremor, postural instability, and balance disturbances.
Conclusions: Health-related quality of life (HRQoL) in patients classified as mild to moderate is not significantly affected by the severity of the disease. Additionally, women have a more favorable perception of their quality of life.
References
Aarsland D., Batzu L., Halliday GM, Geurtsen GJ, Ballard C., Ray Chaudhuri K., Weintraub D. (2021). Dete-rioro cognitivo asociado a la enfermedad de Parkinson. Nat Rev Dis Primers , 7 ( 1 ) , 47. https://doi.org/10.1038/s41572-021-00280-3
Alegre-Ayala J., Vela L., Fernández-Vázquez D., Navarro-López V., Macías-Macías Y., Cano-de-la-Cuerda R. (2023). El impacto de la gravedad de la enfermedad de Parkinson en el desempeño de las ac-tividades de la vida diaria: un estudio observacional. Rev Neurol , 76(8), 249-255. https://doi.org/10.33588/rn.7608.2022263
Antonini, A., Chaudhuri, KR (2018). Aspectos no motores de la enfermedad de Parkinson: una nueva frontera. Trastornos del Movimiento , 3 , https://doi.org/10.1002/mds.27223
Antonini, A., Robieson, WZ, Bergmann, L., Yegin, A., Poewe, W. (2018). Influencia de la edad y la dura-ción de la enfermedad en las actividades de la vida diaria y la calidad de vida después del gel in-testinal de levodopa-carbidopa en la enfermedad de Parkinson. Neurodegener Dis Manag , 8 ( 3), 161-170 . https://doi.org/10.2217/nmt-2017-0046
Barone, P., Antonini, A., Colosimo, C., Graziano, G., Martinelli, P. (2018). Síntomas no motores en la en-fermedad de Parkinson: una revisión crítica. Parkinsonismo y trastornos relacionados , 46, 1-10. https://doi.org/10.1016/j.parkreldis.2017.10.017
Bautista Rodríguez, LM (2016). La calidad en salud un concepto histórico vigente. Revista Ciencia y Cuidado , 13(1 ) , 5. https://doi.org/10.22463/17949831.731
Bastian , AJ y Tondelli, M. (2021) . Enfermedad de Parkinson: diagnóstico, mecanismos y tratamiento. Neurology Review , 40(1), 51-61 . https://doi.org/10.1197/jnr.40.1.051
Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303.
https://doi.org/10.1016/S0140-6736(21)00218-X
Chaudhuri, K. R., & Odin, P. (2020). The challenge of non-motor symptoms in Parkinson’s disease. Pro-gress in Brain Research, 252, 325–341. https://doi.org/10.1016/bs.pbr.2019.10.015
Charcot, JM (1868). Lecciones sobre las enfermedades del sistema nervioso. Adrián , https ://www .ncbi .nlm .nih .gov /labs /p /articles /P /?report =clásico
Chou, YH, Lee, SS (2022) . Síntomas no motores en la enfermedad de Parkinson: una revisión de su im-pacto y manejo. Journal of Neurodegenerative Disease Management , 30 ( 6), 270-281 . https://doi.org/10.1016/j.jndm.2022.04.002
Comisión Económica para América Latina y el Caribe (CEPAL). (2017). El envejecimiento en América Latina y el Caribe: Un desafío para el desarrollo sostenible. https://r.cepal.org/flujo-de-bits/mano/11362/44369/1/S1800629_es.pdf
Deuschl G., Antonini A., Costa J., Śmiłowska K., Berg D., Corvol JC, Fabbrini G., Ferreira J., Foltynie T., Mir P., Schrag A., Seppi K., Taba P., Ruzicka E., Selikhova M., Henschke N., Villanueva G., Moro E. (2022). Guía de la Sección Europea de la Academia Europea de Neurología/Sociedad de Tras-tornos del Movimiento sobre el tratamiento de la enfermedad de Parkinson: I. Terapias invasi-vas. Mov Disord , 37 ( 7 ), 1360-1374. https://doi.org/10.1002/mds.29066
de la Cuadra-Grande, A., Rejas, J., Casado, M. Á., Monroy, M., & Ruiz, M. (2025). Quality of life measures in Parkinson’s disease: A systematic literature review of patient-reported outcome measures (PROMs) and their psychometric properties. Journal of Neurology, 272, Article 598.
https://doi.org/10.1007/s00415-025-13348-x
Giladi, N., Shabtai, H., & Toth, C. (2017). Gender differences in Parkinson's disease progression: a study of motor and non-motor symptoms. Parkinsonism and related disorders , 42, 58-63. https://doi.org/10.1016/j.parkreldis.2017.05.015
González, M., & Pérez, J. (2023). Assessment of quality of life in patients with Parkinson's disease using the SF-36. Journal of Neurology , 56(3), 145-152. https://doi.org/10.1016/j.neurol.2023.01.045
Gülşen ç, koçer B, söke F, özcan gülşen e, yılmaz ö, çomoğlu SS. (2024). The effect of deep brain stimu-lation on lower extremity dexterity in people with Parkinson's disease. Disabil Rehabil, 46(24), 5908-5913. https://doi.org/10.1080/09638288.2024.2317997
Hernández, P., Fernández, M., y Sánchez, E. (2019). Tratamientos farmacológicos y no farmacológicos para la mejora de la calidad de vida en la Enfermedad de Parkinson. Revista Médica de Chile , 147(11), 1586-1592. https://doi.org/10.4067/S0034-98872019001101586
Koivu M, Sihvonen AJ, Eerola-Rautio J, Pauls KAM, Resendiz-Nieves J, Vartiainen N, Kivisaari R, Scheper-jans F, Pekkonen E. (2024). Clinical and brain morphometric predictors of the outcome of deep brain stimulation in Parkinson's disease. Brain Topogr , 37(6), 1186-1194. https://doi.org/10.1007/s10548-024-01054-2
Luo B, Zou Y, Yan J, Sun J, Wei X, Chang L, Lu Y, Zhao L, Dong W, Qiu C, Yan J, Zhang Y, Zhang W. (2024). Impaired cognitive network connectivity in Parkinson's disease during the microinjury period after deep brain stimulation. CNS Neurosci Ther , 30( 12), e70184. https://doi.org/10.1111/cns.70184
Martínez, S., & Ruiz, A. (2021). La medición de la calidad de vida en enfermedades neurodegenerativas: Una revisión del SF-36. Revista Española de Geriatría y Gerontología , 56(5), 205-212. https://doi.org/10.1016/j.regg.2021.06.001
Matus, S., y Vidal, R. (2024). Prevalencia de la enfermedad de Parkinson en Chile: Estimaciones y efec-tos psicoemocionales y sociales. Revista Médica del Maule , 39(4), 123-130. Recuperado de https ://www .revmedmaule .cl
Maiuolo, M. L., De Sarro, G., & Muscoli, C. (2024). Assessment scales for the evaluation of health-related quality of life. Frontiers in Psychology, 15, 1438830. https://doi.org/10.3389/fpsyg.2024.1438830
O'Caoimh R, Foley MJ, Timmons S, Molloy DW. (2024). Detection of cognitive impairment in move-ment disorders: comparison of the Montreal cognitive assessment and the rapid screening test for mild cognitive impairment in Parkinson's disease and Lewy body dementia. J Alzheimer's Dis Rep , 8(1), 971-980. https://doi.org/10.3233/ADR-23020
Organización Mundial de la Salud y Fondo de las Naciones Unidas para la Infancia (UNICEF). (2018). Declaración de Astaná 2018. https ://www .who .int /publications /item /informe -del -conferencia -mundial -sobre -atención -primaria -de -salud -de -alma -ata
Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG, Lin JS. (2022). Screening for cognitive decline in older adults: Evidence update for the U.S. Preventive Services Task Force Rockville (MD ): Agency for Healthcare Research and Quality (U.S.) ) . https://doi.org/10.1177/153331751665382
Pérez-Lloret, S., López-Sendón, JL, Larrad, G., & García-Ruiz, P. (2019). Impacto de los síntomas no mo-tores en la calidad de vida de pacientes con enfermedad de Parkinson. Revista de Neurología , 68(1), 1-8. https://doi.org/10.33588/rn.6801.2018.710
Peña-Zelayeta, L., Delgado-Minjares, K. M., Villegas-Rojas, M. M., León-Arcia, K., Santiago-Balmaseda, A., Andrade-Guerrero, J., Pérez-Segura, I., Ortega-Robles, E., Soto-Rojas, L. O., & Arias-Carrión, O. (2025). Redefining non-motor symptoms in Parkinson’s disease. Journal of Personalized Medi-cine, 15(5), 172. https://doi.org/10.3390/jpm15050172
Pedersen KF, Larsen JP, Tysnes OB, Alves G. (2017). Natural course of mild cognitive impairment in Parkinson's disease: a 5-year population-based study. Neurology , 89(9), 1-8. https://doi.org/10.1212/WNL.0000000000004379
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014). The prevalence of Parkinson’s disease: A systematic review and meta-analysis. Movement Disorders, 29(13), 1583–1590.
https://doi.org/10.1002/mds.25945
Rodríguez-Cid, A., & Jiménez, D. (2021). Neuroprotective agents and clinical management in Parkin-son's disease: advances and perspectives. Journal of Clinical Neurosciences, 27(4), 33-43. https://doi.org/10.1016/j.jocn.2021.02.010
Schafer, E., Gombos, Z., & Szamosi, A. (2022). Parkinson's disease: improvement of patients' long-term health and quality of life. Frontiers in Neurology , 13(7), 1152. https://doi.org/10.3389/fnins.2022.868645
Seppi, K., Fox, SH and MDS Task Force. (2023). Parkinson's disease: a global view. Movement Disorders, 38(5), 1075-1082. https://doi.org/10.1002/mds.28166
Seppi, K., Fox, S. H., Coelho, M., Lam, H., Tsuboi, Y., Kalia, S. K., Lang, A. E., Poewe, W., & Rascol, O. (2023). Update on treatments for nonmotor symptoms of Parkinson’s disease—An evidence-based medicine review. Movement Disorders, 38(5), 681–695. https://doi.org/10.1002/mds.29328
Schavira, AHV, Olanow, CW and Koller, WC (2021). Medical treatment of Parkinson's disease: current status and future directions. Acta Neurologica Scandinavica , 132(1), 1-10 . https://doi.org/10.1111/ane.13322
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. (2022). Systematic review of Parkinson's disease in elderly populations. Cochrane Database Syst Rev , 2022(5), CD002091. https://doi.org/10.1002 /14651858.CD002091.pub3
Van der Heijden, E., & Rosales, J. (2020). Deep brain stimulation for Parkinson's disease: current con-siderations. Cochrane Reviews , 2, 1124-1136. https://doi.org/10/mds.27521
Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA. (2022). Evolution of cognitive dys-function in a cohort of patients with Parkinson's disease. Brain , 135(6), 203https://doi.org/10.1093/brain/awn141
Wu, J., & Xie, Z. (2023). Efficacy of dopamine agonists in the treatment of Parkinson's disease: a com-prehensive review. Neurosci Lett , 782, 136566. https://doi.org/10.101/j.neulet.2023.136566
Zhao, N., Yang, Y., Zhang, L., Zhang, Q., Balbuena, L., Ungvari, G. S., & Xiang, Y.-T. (2021). Quality of life in Parkinson’s disease: A systematic review and meta-analysis of comparative studies. CNS Neu-roscience & Therapeutics, 27(3), 270–279. https://doi.org/10.1111/cns.13549
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Eduardo Cruzat Bravo, Rocio Bustos Barahona, David Ergas Schleef, Mauricio Tauda Tauda
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and ensure the magazine the right to be the first publication of the work as licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of authorship of the work and the initial publication in this magazine.
- Authors can establish separate additional agreements for non-exclusive distribution of the version of the work published in the journal (eg, to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Is allowed and authors are encouraged to disseminate their work electronically (eg, in institutional repositories or on their own website) prior to and during the submission process, as it can lead to productive exchanges, as well as to a subpoena more Early and more of published work (See The Effect of Open Access) (in English).
This journal provides immediate open access to its content (BOAI, http://legacy.earlham.edu/~peters/fos/boaifaq.htm#openaccess) on the principle that making research freely available to the public supports a greater global exchange of knowledge. The authors may download the papers from the journal website, or will be provided with the PDF version of the article via e-mail.
